# Brendan Bulik-Sullivan

> Brendan Bulik-Sullivan is a General Partner at GV (Google Ventures) backing biotech and therapeutics companies from the San Francisco office. He arrived at venture capital by a back door familiar to almost no one: a Ph.D. in statistical genetics, an authorship on the LD Score Regression method that reshaped how human geneticists read GWAS data, and a stint designing the deep-learning neoantigen models at Gritstone Oncology. He now sits on the boards of Comanche Biopharma, Santa Ana Bio, Ventus Therapeutics, and Areteia Therapeutics.

- **Role:** General Partner at GV (Google Ventures)
- **Organizations:** GV (Google Ventures), Gritstone Oncology (alum), Broad Institute of MIT and Harvard (alum), Comanche Biopharma (board), Santa Ana Bio (board), Ventus Therapeutics (board), Areteia Therapeutics (board observer)
- **Nationality:** American
- **Education:** B.A. in Mathematics, University of California, Berkeley, Ph.D. in Statistical Genetics, Vrije Universiteit Amsterdam
- **Known for:** Co-author of the LD Score Regression method (ldsc), a widely used tool for estimating heritability and genetic correlation from GWAS summary statistics., Co-author of the Gritstone deep-learning neoantigen identification paper in Nature Biotechnology (2018)., Publications in Nature, Science, Nature Biotechnology, and Nature Genetics.

## Career timeline

- **~2015** — Co-authored 'LD Score Regression Distinguishes Confounding from Polygenicity in GWAS' in Nature Genetics while at the Broad Institute's Stanley Center for Psychiatric Research.
- **2016** — Joined Gritstone Oncology to lead machine learning work on personalized immuno-oncology therapeutics.
- **2018** — Co-authored 'Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification' in Nature Biotechnology.
- **2019** — Joined GV in the San Francisco office to invest in biotech and therapeutics.
- **2023-06** — Promoted to General Partner at GV alongside three colleagues.

## Achievements

- Co-author of the LD Score Regression method (ldsc), a widely used tool for estimating heritability and genetic correlation from GWAS summary statistics.
- Co-author of the Gritstone deep-learning neoantigen identification paper in Nature Biotechnology (2018).
- Publications in Nature, Science, Nature Biotechnology, and Nature Genetics.
- Recognized by Business Insider among up-and-coming investors changing healthcare (2020).
- Led GV investments in Comanche Biopharma, Santa Ana Bio, Ventus Therapeutics; Maze Therapeutics and Metsera among exits.

## Latest updates

- **2023-06** — Promoted to General Partner at GV.
- **2020-10** — Named by Business Insider as one of the up-and-coming investors reshaping healthcare.

## Links

- Website: https://www.gv.com/team/brendan-bulik-sullivan
- LinkedIn: https://www.linkedin.com/in/brendan-bulik-sullivan-b2595592
- GitHub: https://github.com/bulik

---

Profile page: https://yespress.io/brendan-bulik-sullivan
Published by YesPress — https://yespress.io
Last updated: 2026-05-20